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ABSTRACT  
Objective: The objective of the study was to formulate and evaluate the nanoproniosomal gel of Enalapril maleate (EM) for the treatment of 
hypertension through the transdermal administration and to provide better bioavailability. 
Methods: The nanoproniosomal gel of the EM was formulated by Lecithin, Cholesterol, Non-ionic surfactants using the Coacervation-phase 
separation method. The prepared nanoproniosomal gels were evaluated for pH and viscosity, vesicle size analysis, rate of spontaneity, entrapment 
efficiency, zeta potential, ex vivo skin permeation studies, skin irritation test, stability studies and in vivo antihypertensive studies. 
Results: Physical characterization was found to be within acceptable limits. The ex vivo skin permeation studies showed the cumulative permeation 
of 58.75 % to 89.72 % through the albino rat skin in 24 h for all the formulations, which indicate the zero-order drug permeation with diffusion, 
non-fickian release. Among all formulations, EMNP7 was selected as best formulation because it showed better characteristics than other 
formulations in several aspects like physicochemical characterization, ex vivo skin permeation studies, permeation kinetics, and other evaluation 
parameters. The skin irritation study revealed that there was no irritation after topical application and it was found to be safer to use. The In vivo 
antihypertensive study revealed that the formulation of EMNP7 was successful to regress the rat blood pressure (BP) to normal values in 
experimental hypertensive rats.  
Conclusion: The nanoproniosomal gel is an efficient transdermal therapeutic system for the delivery of EM for the treatment of hypertension. It is 
suitable for once a day controlled release formulation. 
Keywords: Cholesterol, Enalapril maleate, Ex vivo Permeation studies, In vivo antihypertensive studies, Lecithin, Nonionic surfactants, Proniosomes, 
Skin irritation studies, Transdermal gel 
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INTRODUCTION 
Nowadays, transdermal delivery is the most successful and fruitful drug 
delivery system and became an inventive target for research in drug 
delivery. It delivers the drug into the systemic circulation at a 
predetermined and controlled rate through the skin. It has some 
advantages such as a non-invasive route, self-administration, bypasses 
the gastrointestinal tract, reduces the dosage with side effects, increases 
patient compliance with safety, enhances the bioavailability with 
therapeutic efficiency. In recent years, various novel concepts are 
developed to achieve controlled or targeted delivery of drugs with the 
safest administration. Among them, vesicular carriers such as 
proniosomes, liposomes, niosomes, ethosomes, etc. are used to attain 
controlled and targeted drug delivery [1-3]. 
Proniosomes are nano-sized vesicular structures of dry, free-flowing 
powder (or) gel with drug encapsulation in the vesicle that produce 
multilamellar niosomal dispersion after hydration. The Proniosome 
powder is hydrated into niosomal suspension immediately before 
administration by brief agitation with a hot aqueous medium which 
is convenient for oral or other routes; and in case of proniosomal gel, 
proniosomes are converted into niosomes in situ by absorbing the 
water from the skin after topical application. This mechanism was 
shown in fig. 1 [4-6]. 
 
 
Fig. 1: Conversion of proniosome into noisome [7] 
 
Priniosomal gels are semisolid products formed by the coacervation 
phase separation method, which involves the admixture of nonionic 
surfactant, cholesterol in a minimal amount of alcohol with 
subsequent hydration in aqueous media. They appear as a clear, 
transparent, or translucent semisolid gel texture, which makes them 
stable physically during storage. They provide the controlled drug 
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release, enhancement of drug penetration with reduced toxic effects; 
and also prevent the other physical stability problems of niosomes 
such as aggregation, fusion, leaking, and have additional transport, 
distribution, storage, dosing and design convenience [8-10]. 
The proniosomal delivery has attracted the transdermal route for 
the potential delivery of drugs because both nonionic surfactants 
and phospholipids themselves act as penetration enhancers. The 
non-ionic surfactant and cholesterol ratio can alter both the release 
characteristics and the encapsulation efficiency of the entrapped 
drugs. It also improves the release and permeation of active agents 
via skin and also governs the rate of the drug release mechanism. 
After the application of proniosomes to the skin, they get hydrated 
to form niosome vesicles, and a high thermodynamic activity 
gradient develops at the contact, which increases the permeability of 
the drug. Thereby, the drug penetrates the skin layers and it can be 
absorbed into systemic circulation via capillaries. The mechanism of 
permeation was shown in fig. 2. The Gels became more familiar 
because of ease of applicability, good percutaneous permeation, 
controlled drug release characteristics than other semi-solid 
preparations. Hence, proniosomes are commonly prepared in gel 
formulation [6, 7, 11]. 
 
 
Fig. 2: Mechanism of permeation [7] 
 
EM is an Angiotensin-Converting Enzyme inhibitor commonly 
employed to treat hypertension and congestive heart failure. It is a 
suitable drug for anti-hypertensive therapy because of low toxicity 
and high efficiency. EM possesses ideal characteristics such as a low 
molecular weight, which is 492.53 (below 600 daltons), smaller dose 
range (2.5-20 mg), short plasma half-life (1.3 h), and poor oral 
bioavailability (50-60 %) for suitability as a transdermal 
formulation. Hence, it was selected in the nanoproniosomal gel 
formulation for the transdermal route [12-14]. The prime goal of the 
investigation was to formulate the nanoproniosomal gel of EM for 
the efficient treatment of hypertension through the transdermal 
route and to provide better bioavailability. 
MATERIALS AND METHODS 
Materials 
EM was obtained as a gift sample from Lee Pharma Limited, 
Hyderabad, India. Cholesterol, Soya Lecithin, Span 20, Span 40, 
Tween 60, Tween 80 were obtained from Himedia Laboratories Pvt. 
Ltd, Mumbai, India. Brij 30, Brij 72 were obtained from Sigma-
Aldrich, Hyderabad, India. Methylprednisolone acetate (MPA) 
injection (Depo-MedrolTM) manufactured by Pfizer was purchased 
from a medical shop. All other chemicals and reagents used were of 
research-grade. 
Methods 
Standard curve of pure drug 
It was carried out by preparing the stock solution by dissolving 100 
mg of the drug in 100 ml phosphate buffer pH 7.2 to obtain 1 mg/ml 
concentration. Then serial aliquots were prepared to produce different 
concentrated sample solutions in the range of 2-20 μg/ml. The 
samples were analyzed against the blank by using the Ultra Violet (UV) 
spectroscopy at an absorption maximum of 206 nm [15-17]. 
Drug-Excipient compatibility study 
Fourier Transform-Infrared Spectroscopy (FT-IR Spectroscopy) was 
done to investigate and predict the physicochemical interaction 
between formulation components such as lecithin, cholesterol with 
drug substance. A small amount of sample was mounted on the 
sample handling stage and scanned in an FTIR spectrophotometer. 
The IR spectrum of the pure drug was compared with the physical 
mixtures of drug and excipients, and peak matching was carried out 
to determine the disappearance or appearance of peaks [18-20]. 
Preparation of nanoproniosomal gel 
It was prepared by the Coacervation-phase separation method. In this 
method, the nonionic surfactants were weighed and put in a wide 
mouth glass vial with a tightly screwed cap. Then an accurate amount 
of drug, cholesterol, and lecithin was added to the glass vial. After 
mixing all these ingredients in a glass vial, ethanol was included and 
mixed up thoroughly. Heat the above solution until the cholesterol, 
lecithin, and drug were completely dissolved in surfactant until the 
appearance of a clear gel (Usually it takes about 20-25 min for soya 
lecithin to completely dissolve in surfactant). To this clear solution like 
gel, then add 0.1 % glycerol solution (it acts as an aqueous phase) and 
was gently heated until a clear solution (usually it takes about 10 min) 
obtained, later cooled down while mixing it with a glass rod at regular 
intervals. Finally, that results in the formation of nanoproniosomal gel 
[21-23]. The schematic representation of this method was shown in 
fig. 3. The formulation was shown in table 1. 
Evaluation of nanoproniosomal gel 
pH 
The pH of the proniosomal gel formulations was performed in 
triplicate by using the calibrated digital pH meter [25]. 
Viscosity 
The viscosity of the formulations was measured by using Brookfield 
Viscometer (DV-E). 10 g of the gel was taken into a beaker, the 
spindle of a viscometer was dipped into the gel and then viscosity 
was determined by rotating the spindle 06 at 100 rpm [23, 25]. 
Vesicle size determination (Microscopic evaluation) 
The required quantity of proniosomal gel (100 mg) was hydrated with 
Phosphate Buffer Saline (10 ml) in a small vial and was manually 
shaken for 5 min. The formed niosomes were microscopically 
examined by an optical microscope at 100 X magnification. The 
average size of vesicles was measured using calibrated ocular and 
stage micrometers in the microscope [9, 22, 26]. 
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EMNP1 EMNP2 EMNP3 EMNP4 EMNP5 EMNP6 EMNP7 EMNP8 EMNP9 EMNP10 EMNP11 EMNP12 EMNP13 
Drug 10 10 10 10 10 10 10 10 10 10 10 10 10 
Lecithin 100 100 100 100 100 100 100 100 100 100 100 100 100 
Cholesterol 100 100 100 100 100 100 100 100 100 100 100 100 100 
Span 20 1000 -- -- -- -- -- 500 -- -- 500 500 -- -- 
Span 40 -- 1000 -- -- -- -- 500 -- -- -- -- 500 500 
Tween 60 -- -- 1000 -- -- -- -- 500 -- 500 -- 500 -- 
Tween 80 -- -- -- 1000 -- -- -- 500 -- -- 500 -- 500 
Brij 72 -- -- -- -- 1000 -- -- -- 500 -- -- -- -- 
Brij 30 -- -- -- -- -- 1000 -- -- 500 -- -- -- -- 




QS QS QS QS QS QS QS QS QS QS QS QS QS 
 
 
Fig. 3: Coacervation phase separation method [24] 
 
Rate of spontaneity 
Spontaneity can be defined as the number of niosomes produced 
spontaneously upon hydration of proniosomes for 15-20 min. The 
specified quantity (10 or 20 mg) of proniosomal gel was transferred 
into a clean stoppered glass container and was spread along the 
walls of a glass container uniformly with the help of a glass rod. 
Then, 2 ml of saline solution (0.9 % NaCl) was added cautiously to 
the walls of a glass container and kept aside in an undisturbed 
position for 20 min. After that, a drop of this solution was placed on 
the Neubauer's chamber to count the number of vesicles (niosomes) 
formed from proniosomes [9, 21, 27]. 
Entrapment efficiency 
To assess the stacking limit of the proniosomal frameworks for EM, 
the proniosomal gel (100 mg) was scattered in refined water and 
warmed a little for the development of niosomes. This dispersion 
was centrifuged at 18 000 rpm for 40 min at 5 °C (Remi CPR-24 
axis). The supernatant portion was utilized for the assurance of free 
medication at 206 nm by spectrophotometrically [9, 27]. 
The rate of entrapment efficiency was determined from 




Ethical clearance approval  
Ethical clearance was obtained from the Institutional Animal Ethical 
Committee (IAEC) for the handling of experimental animals for 
evaluation tests such as Ex Vivo Skin permeation studies, Skin 
irritation studies, and In vivo antihypertensive studies. The protocol 
of the animal study was approved by IAEC, Protocol Number: 
SVCP/IAEC/II-012/2019-20 dt 18.11.19. The experiment was 
carried out as per the guidelines of the Committee for the purpose of 
control and supervision of experiments on animals (CPCSEA). 
Ex vivo skin permeation studies 
Albino rats weighing 150-200 g were selected for permeation study. The 
rats were obtained from Sree Venkateshwara Enterprises, Bengaluru. 
The animals were kept under standard laboratory conditions, with a 
temperature of 25±1 °C and relative humidity of 55±5 %. They are 
placed properly in animal cages with free access to diet and water. The 
Rat was sacrificed using anesthetic ether, and hair of the test animal was 
trimmed short (<2 mm) with scissors. Approximately 4.5 to 5.0 cm2 of 
the full thickness of the skin was excised from the shaved abdomen site. 
After the removal of the subcutaneous fat, the skin sample was washed 
in distilled water and an isotonic phosphate buffer. The separated skin 
was cut into the required size and wrapped in aluminum foil and stored 
in a deep freezer at-20 °C until further use (used within two weeks of 
preparation). 
These studies were performed by using a modified Franz-diffusion 
cell. It contains a receptor compartment with a volume of 
approximately 60 ml and a surface area approximately 3.14 cm2for 
permeation. The excised albino rat skin was incorporated between 
the donor and receptor compartments. A precise quantity of 
proniosomal gel was placed above the skin towards the donor 
compartment and the receptor compartment was filled with 
phosphate saline buffer pH 7.2. The heat was provided to maintain 
the required temperature at 370.5 °C by using a thermostatic hot 
plate fixed to a magnetic stirrer. The receptor diffusion medium was 
stirred by a Teflon-coated magnetic bead placed inside a receptor 
compartment. 
At appropriate time intervals, samples were withdrawn and were 
replaced by equal volumes of fresh receptor fluid on each 
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withdrawal, and samples were analyzed spectrophotometrically at 
206 nm [9, 18, 21, 22, 28]. 
Release kinetics 
To determine the mode and mechanism of drug release, the data 
obtained from the ex vivo permeation profiles were fitted in various 
kinetic models such as zero-order kinetic model (cumulative % drug 
release versus time), first-order kinetic model (log cumulative of % 
drug remaining versus time), Higuchi's model (cumulative % drug 
release versus square root of time) and Korsmeyer-peppa’s model 
(log cumulative % drug release versus log time) [18, 19, 29]. 
Permeation kinetic studies 
Permeability coefficient (P) 
It is the capability of drug permeation through the semi-permeable 
membrane in mg/cm2/h. It was determined from the slope of the 
plot of the percentage of drug transported versus time, was 
calculated by dividing Jss by the initial drug concentration of the 





Flux (Jss)  
It is defined as the amount of substance passing through a unit 
cross-sectional barrier in unit time. It was determined from the 
slope of the plot of the percentage of drug transported versus time, 
and it was calculated by, dividing the slope of the linear portion of 
the plot by the surface area of the diffusion cell. 
Jss =
Slope of the plot
Surface area of the diffusion cell
 
Enhancement ratio (Er)  
It is an important parameter used to determine the effect of 
permeation enhancer on diffusion and permeability characteristics 
of the drug substance. It was calculated by, dividing the Jss of the 
particular formulation by the Jss of the control formulation [30, 31]. 
Er =
Jss of the formulation
Jss of the control
 
Semi electron microscopy (SEM) 
It was carried out to evaluate the morphological features of the 
niosomes, which were formed upon hydration of proniosomal 
formulations. In this study, a precise quantity of proniosomal gel was 
diluted with phosphate buffer pH 7.2 in a glass test tube and the 
formed vesicles were dispersed on an adhesive carbon tape placed on 
an aluminum stub. The samples were coated with gold using a vacuum 
evaporator (3×10-1atm) and were examined at 25 kV accelerating 
voltage under SEM fitted with a digital camera [18, 22, 26]. 
Zeta potential 
It is a measure of net charge on the surface of niosomes. If zeta 
potential increases, then the repulsive forces between the vesicles 
also increase, which prevents the agglomeration of vesicles and 
produces evenly distributed and stable niosomal suspension. It was 
determined by using a HORIBA SZ-100 Zeta meter [18, 21, 32]. 
Skin irritation studies 
The skin irritation test was done on healthy albino rats weighing 
between 160 to 180 g. It was carried out as per the guidelines of 
Organisation for Economic Co-operation and Development (OECD). 
The rats were obtained from Sree Venkateshwara Enterprises, 
Bengaluru. The animals were kept under standard laboratory 
conditions, with a temperature of 25±1 °C and relative humidity of 
55±5 %. They are placed properly in animal cages with free access to 
diet and water. On the previous day of the experiment, the hair on 
the backside of the animal was removed. In this study, 0.5 g of 
proniosomal gel was applied to 3 rats on an area of skin 
approximately 1"x1" (2.54 x 2.54 cm) square, and animals were 
placed in their cages. After the exposure to 24 h, the proniosomal gel 
was removed and the test sites were washed with tap water to 
remove any sign of test article residue. This study was performed on 
one rat initially (Initial skin irritation test) and later conducted on 
two rats (confirmatory skin irritation test). The Erythema and 
Edema were to be observed. Finally, the test sites were to be graded 
as per the visual scoring scale [22, 28, 33-35]. 
The erythema scale is as follows:  
0. none 
1. slight 
2. well defined 
3. moderate 
4. scar formation 
The edema scale is as follows:  
0. none 
1. slight 




The stability of a product is defined as the potential of a specific 
dosage form in a suitable container to remain with the physical, 
chemical, microbiological, therapeutic, and toxicological 
characteristics at the time of manufacture. The stability study was 
conducted as per the International Conference on Harmonisation 
(ICH) guidelines and it was done to detect the drug degradation 
from proniosomal gel during the storage period. In this study, the 
prepared formulations were stored at Refrigeration Temperature 
(4-8 °C), Room Temperature (252 °C), Oven (452 °C) for 45 d. The 
proniosomal formulation was stored in aluminum foil sealed glass 
vials for all over the study. At different time intervals, samples were 
collected and analyzed for drug content, physical appearance, 
homogeneity, vesicle size, pH, and a viscosity [9, 22, 36]. 
In vivo antihypertensive studies 
Healthy male Albino Wistar rats were (weighing approximately 
250±25 g) selected for this study, and all the animals were healthy 
during the period of the experiment. The animals were kept under 
standard laboratory conditions, with a temperature of 25±1 °C and 
relative humidity of 55±5 %. The animals were placed properly in 
polypropylene cages, 6 per cage, with free access to a standard 
laboratory diet (Lipton feed) and water ad libitum. The dose for the 
rats was determined based on the body weight and surface area ratio. 
Thirty rats were taken and separated into five categories (Group A 
to E), each carrying six rats. Group A was considered as control and 
hypertension was induced in other rats (Group B to E) by injecting 
MPA (20 mg/kg/w) subcutaneously for two weeks. Treatments 
given to each group were indicated in table 2. 
  
Table 2: Treatment given to the different groups of animals 
S. No. Group Treatments No. of rats in group Measurement of BP at different time intervals (h) 
1 A Control 6 0, 1, 2, 3, 4, 6, 8, 10, 12, 24 
2 B Only MPA 6 0, 1, 2, 3, 4, 6, 8, 10, 12, 24 
3 C MPA+placebo EMNP7 6 0, 1, 2, 3, 4, 6, 8, 10, 12, 24 
4 D MPA+EMNP7 6 0, 1, 2, 3, 4, 6, 8, 10, 12, 24 
5 E MPA+Marketed tablet 6 0, 1, 2, 3, 4, 6, 8, 10, 12, 24 
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Before the application of the gel, the rat skin was first visually 
evaluated to check normal skin condition. Then, the dorsal part of the 
hair was carefully shaved or clipped without damaging the stratum 
corneum, and the skin was gently wiped with warm water followed by 
an alcohol swab and patted dry. Then, selected formulation EMNP7 
was applied evenly to the surface of the previously shaven area of rat 
skin. To keep the gel secured at the site of application, the 
microporous adhesive tape was rolled over the gel. Then rats were 
placed in the animal holder and had free access to water and food. 
Then BP was determined from the rat tail at predetermined time 
intervals up to 24 h using the rat BP instrument (Biopac system, USA) 
and based on a non-invasive BP measuring method. The device 
consists of a scanner, a tail-cuff, an animal holder attached to the main 
instrument having a digital BP display panel [37-39]. 
Statistical analysis: The data was statistically analyzed by using a 
one-way analysis of variance. A Dunette multiple comparison test 
and paired t-test using GRAPHPAD INSTAT 3 software (Graph-Pad 
Software Inc.) were used to test the different formulations and the 
level of significance was taken as p<0.05. 
RESULTS AND DISCUSSION 
Preparation of standard curve of EM 
The standard curve of the pure drug was constructed by using 
phosphate buffer pH 7.2. The slope of the given data was found to be 
0.0468 and regression was found to be R² = 0.9998. The present 
analytical method suggests that the drug obeyed the Beer's 
lambert's linearity principles within limits of 2 to 20 (µg/ml) and 
was suitable in the estimation of EM in phosphate buffer 7.2 at 206 
nm by UV spectrophotometer. The standard curve table and graph 
were shown in table 3 and fig. 4, respectively. 
Drug-excipient compatibility study 
FT-IR Spectra of all excipients do not show any significant changes in 
the functional group and fingerprint region, indicating no interaction 
between pure drug and excipients. These results depicted that the 
EM is compatible with selected excipients in nanoproniosomal 
formulation. The graphs of FTIR spectra were shown in fig. 5 and 6 
and their interpretation was shown in table 4, respectively. 
 
Table 3: Construction of standard curve in phosphate buffer 7.2 














Fig. 4: Construction of standard curve in phosphate buffer 7.2 
 
Table 4: Interpretation of FT-IR of drug 
S. No. Wave in cm Functional group 
1 3025.75 C-H Aromatic stretching 
2 1597.24 Benzene ring 
3 1597.24, 1727.80 Carbonyl group 
4 1361.56 -OH group 
5 1361.56, 1300.42 Tertiary aromatic nitrogen 
6 1267.85, 1361.56 Secondary aliphatic amine 
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Fig. 5: FT-IR spectra of pure EM 
 
 
Fig. 6: FT-IR spectra of the physical mixture of enalapril, lecithin, and cholesterol 
 
Physicochemical characterization of proniosomal gel 
The EM nanoproniosomal gel was characterized for physicochemical 
properties and the results were given in table 5.  
The pH of all the formulations was around 6.7 and 7.3, which means 
that they are safer to administer through the transdermal route.  
The vesicle size of the formulations was found to be in the range of 
5.2-21.6 µm that shows the spans (Span 20, Span 40) form smaller 
size vesicles and greater encapsulation efficiency than tweens and 
brij surfactants. The results were in good agreement with 
Khanderao R. Jadhav et al. (2016) who described that spans form 
smaller size vesicles when compared with other nonionic 
surfactants [24]. 
The rate of the spontaneity of the formulations was found to be in 
the range of 8-16, which indicates the number of niosomes formed 
from the proniosomes after hydration. 
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The Entrapment Efficiency of the formulations was found to be in 
the range of 53.36 %-85.23 % and the viscosity of the formulations 
was obtained in the range of 8751-12340 cps. The results were 
accepted with Khanderao R. Jadhav et al. (2016), who described that 
surfactants having hydrophilic-lipophilic balance in the range of 4 to 
8 produce stable proniosomes with good entrapment efficiency [24]. 
All the prepared formulations showed good physicochemical 
characteristics and are within limits. 
 
Table 5: Physicochemical characterization 
Formulation code pH* Vesicle size* (µm) Rate of spontaneity* Entrapment efficiency %* Viscosity (cps)* 
EMNP1 6.7±0.45 8.3±0.80 10±3.07 80.61±0.28 10496±1.72 
EMNP2 6.8±0.03 7.5±0.42 13±0.73 82.46±0.47 11307±1.59 
EMNP3 7.0±0.63 20.2±1.34 9±2.58 53.36±0.41 11824±3.96 
EMNP4 7.2±0.57 21.6±1.05 8±1.62 55.52±0.98 12067±2.58 
EMNP5 6.9±0.48 12.7±2.83 14±1.04 74.94±0.57 8751±1.97 
EMNP6 7.1±0.52 16.4±1.72 12±2.95 73.65±0.51 9374±3.86 
EMNP7 6.9±0.74 5.2±0.64 16±0.21 85.23±0.78 10786±2.05 
EMNP8 7.2±0.34 17.7±0.36 10±3.46 62.81±0.73 9793±2.82 
EMNP9 6.8±0.61 14.8±3.61 11±2.84 71.27±0.75 10583±2.62 
EMNP10 7.1±0.06 18.5±2.95 15±1.76 66.19±0.82 10220±1.63 
EMNP11 7.2±0.32 11.2±2.24 12±2.08 75.83±0.46 10748±2.95 
EMNP12 6.8±0.05 15.5±3.02 10±3.65 77.68±0.13 11526±3.74 
EMNP13 7.3±0.08 12.4±1.87 13±1.94 76.29±0.35 12340±1.85 
*Average of three values, Standard deviation 
 
Microscopic evaluation 
The microscopic evaluations of the formulation showed that the 
formulations are in good physical shape and size. The microscopic 
images were shown in fig. 7 to 9. 
Ex vivo skin permeation studies 
The skin permeation data of the formulations were shown in table 6 and 
fig. 10. The percentage drug permeation of EMNP7 was found to be the 
highest among all, around 89.72 %, than other formulations. The 
decrease in vesicle size due to nanoproniosomal technology may be the 
reason for the increase in drug diffusion rate and extent. The results 
were compared with Ankur Gupta et al. (2007) who studied the 
Proniosomal transdermal system of an antihypertensive drug, Captopril 
showed less % of drug permeation than our formulation [9] and also 
with Venkata Ramesh Yasam et al. (2014) who studied the Proniosomal 
transdermal delivery of an antihypertensive drug, Nifedipine showed 
less % of drug permeation than our formulation [18]. 
 
 
Fig. 7: Microscopic image of EMNP7 (Before and after hydration) formed from spans 
 
 
Fig. 8: Microscopic image of EMNP3 (Before and after hydration) formed from tweens 
 
 



















































































































*Average of three values, Standard deviation 
 
 
Table 7: Cumulative percentage and kinetic data obtained from different formulations
Formulation 
code 
Percentage of drug permeated 
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Table 6: Ex vivo skin permeation studies* 
 EMNP5 EMNP6 EMNP7 EMNP8 EMNP9 EMNP1
0 





























































































































































Fig. 10: Ex vivo skin permeation study chart 
Zero-order plot First-order plot Higuchi plot
Regression Regression Regression
0.984 0.667 0.965 
0.990 0.681 0.960 
0.996 0.728 0.944 
0.990 0.721 0.934 
0.992 0.693 0.954 
0.992 0.692 0.948 
0.987 0.661 0.966 
0.986 0705 0.965 
0.989 0.679 0.961 
0.995 0.722 0.952 
0.994 0.748 0.948 
0.993 0.723 0.930 






































































































 Korsmeyer-peppa’s plot 
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Fig. 11: Kinetic drug release plots of best formulation EMNP7 
 
Release kinetics 
All the formulations from EMNP1 to EMNP13 showed zero-order 
profile with diffusion, non-fickian release as the possible 
mechanisms of drug release. From the Higuchi model, the drug 
permeation was thought to be following the diffusion model. From 
the Korsmeyer peppa's plot, the drug permeation showed the Non-
fickian release. Thus, suggesting that the proniosomal gels could 
meet the controlled release characteristics. The kinetic data were 
shown in table 7 and the kinetic drug release plots of the best 
formulation were shown in fig. 11. The results were in good 
acceptance with Shanti Sagar et al. (2017) who studied the release 
kinetics of proniosomal gel of capecitabine [40] and also with Indira 
U et al. (2012) who described that in Korsemeyer-peppa’s plot, if the 
release exponent n value near to 0.5, then the drug release 
mechanism is Fickian diffusion and if n have a value near 1.0 then it 
is non-Fickian diffusion [4]. 
Permeation data analysis 
The permeability parameters such as permeation coefficient, flux, 
enhancement ratio were significantly increased in nanoproniosomal 
formulations. Among them, EMNP7 showed better permeation data 
than other formulations. The kinetic permeation data was shown in 
table 8. The results were in good accordance with Faiyaz Shakeel et 
al. (2007) and Sadashivaiah R et al. (2008) who studied the 
permeation data analysis of aceclofenac and haloperidol lactate 
through transdermal route respectively [30, 31]. 
 
Table 8: Ex vivo permeation kinetics 
S. No. Formulation code Permeation coefficient (P) (mg/cm2/h)* Flux (Jss) (mg/cm2/h)* Enhancement ratio (Er)* 
1 Control 1.21 0.242 - 
2 EMNP1 2.14 0.428 1.76 
3 EMNP2 2.27 0.454 1.88 
4 EMNP3 1.92 0.384 1.59 
5 EMNP4 1.77 0.354 1.46 
6 EMNP5 2.08 0.416 1.72 
7 EMNP6 1.98 0.396 1.64 
8 EMNP7 2.38 0.476 1.97 
9 EMNP8 1.59 0.318 1.31 
10 EMNP9 2.21 0.442 1.82 
11 EMNP10 1.73 0.346 1.43 
12 EMNP11 1.70 0.340 1.40 
13 EMNP12 1.81 0.362 1.45 
14 EMNP13 1.49 0.298 1.23 
 
Among all formulations, EMNP7 was shown good physicochemical 
characteristics, better skin permeation, and permeation kinetics. 
Hence, it was selected as the best formulation for further studies 
such as SEM, zeta potential analysis, skin irritation studies, stability 
studies, and In vivo antihypertensive studies. 
Scanning electron microscopy 
The best formulation EMNP7 was selected for the SEM analysis. It 
showed good surface morphology. It was shown in fig. 12. 
Vesicle size and zeta potential analysis 
The size of nanoproniosomal gel plays a vital role in drug release; 
hence it is an important parameter to be determined. The vesicle 
size and the PI value of the best formulation were determined as 
185.2 nm and 0.492 (which indicates very broad distribution). Zeta 
potential measurement is very important because it indicates the 
stability of vesicles. The high value of zeta potential (more than±30 
mV) shows greater repulsion between charged particles, which 
reduces aggregation or flocculation and enhances the stabilization of 
vesicles. The Zeta potential of the best formulation was found to be-
84.0 mV and reported as excellent stability. The vesicle size and 
potential zeta graphs were shown in fig. 13 to 15. The results were 
in good accordance with Ali Nasr et al. (2018) who described that 
particles with zeta potential values more than (+30 mV) or less than 
(-30 mV) are considered stable and negative values indicate the 
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Fig. 12: SEM image of best formulation EMNP7 
Fig. 13: Vesicle size of nanoproniosomal gel of EM 
 
 14: Vesicle size chart of nanoproniosomal gel of EM 
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Fig. 16: Skin irritation test of proniosomal gel on albino rat 
 
Skin irritation studies 
The skin irritation test was performed according to OECD guidelines 
and the results showed no changes like Edema and Erythema. Hence, 
the formulation passed the skin irritation test and is safe to be used 
on Human skin. The skin irritation test images were shown in fig. 16. 
Stability studies 
Physical appearance and homogeneity were found to be good during 
the storage period. The Stability studies performed showed that the 
formulation EMNP7 is highly stable at different temperatures for the 
prescribed time. Hence, the formulation passed the stability studies. 
The stability data were shown in table 9. The results were in good 
accordance with Viney Lather et al. (2016), who performed the 
stability studies of the proniosomal gel of bromocriptine through 
transdermal delivery [22]. 
In vivo antihypertensive studies 
In this study, the normal healthy rats were successfully induced with 
hypertension by injecting MPA for two weeks and they remained 
hypertensive for 72 h after stopping the MPA injection. The 
Proniosomal gel formulation EMNP7 was found to decrease the BP 
significantly (p<0.001) in proximity to the normal value and it was 
maintained for 24 h (table 10). This indicates that the drug was 
permeated and constantly released into the systemic circulation up 
to 24 h in rats. However, post-treatment BP values in the treatment 
group (D) were comparable with the control group (A). On 
comparing the effects of all the systems, the percentage reduction in 
mean rat BP by EMNP7 and Placebo EMNP7 was 26.03 % and 0.13 
%, respectively (table 10). EMNP7 was successful in reverting the 
rat BP to normal values. The above results suggest that the 
formulation EMNP7 holds a promising future for the management of 
hypertension, which needs to be validated by clinical trials. The 
results were in good accordance with Abdul Ahad et al. (2014) who 
investigated the antihypertensive activity of the proniosomal gel of 
an antihypertensive drug, valsartan for transdermal delivery [37]. 
 
Table 9: Stability data 
Storage period  4 °C* 
Vesicle size Entrapment efficiency Viscosity pH 
15 d 5.2±0.20 84.2±0.15 10805±0.72 6.9±0.16 
30 d 5.1±0.14 83.9±0.26 10814±0.85 6.9±0.13 
45 d 5.0±0.12 82.1±0.18 10823±0.76 6.9±0.25 
Storage period  25 °C* 
Vesicle size Entrapment efficiency Viscosity pH 
15 d 5.2±0.12 84.8±0.35 10793±0.58 6.9±0.12 
30 d 5.2±0.21 84.2±0.22 10801±0.42 6.9±0.06 
45 d 5.0±0.18 83.4±0.45 10815±0.26 6.9±0.08 
Storage period  40 °C* 
Vesicle size Entrapment efficiency Viscosity pH 
15 d 5.2±0.06 85.6±0.28 10781±0.39 6.9±0.15 
30 d 5.2±0.14 85.3±0.51 10785±0.46 6.9±0.23 
45 d 5.2±0.23 85.2±0.48 10788±0.32 6.9±0.04 
 *Average of three values, Standard deviation 
 
Table 10: Influence of proniosomal gel formulation of EM on mean BP in MPA induced hypertensive rats 
S. No. Group Treatments Mean BP (mm Hg)* % Reduction 
in BP* Pre-treatment Post-MPA treatment Post proniosomal gel treatment 
1 A Control 121.32±10.05 -- -- -- 
2 B Only MPA 122.15±8.27 163.45±11.32 -- -- 
3 C MPA+placebo EMNP7 122.46±12.36 162.37±12.15 162.16±11.26 0.13±0.03 
4 D MPA+EMNP7 121.53±11.08 163.76±13.21 121.12±8.79 26.03±1.24 
5 E MPA+Marketed tablet 122.71±6.82 161.28±11.18 140.63±10.14 12.80±1.85 
 *Average of six values, Standard deviation 
 
CONCLUSION 
The nanoproniosomal gel of the EM was formulated to improve the 
bio-availability and permeation of the drug through the skin for the 
effective treatment of hypertension. Various formulations of the 
nanoproniosomal gel were prepared by the coacervation phase 
separation method. Among those formulations, EMNP7 showed 
better characteristics than other formulations in several aspects like 
entrapment efficiency, vesicle size, ex vivo permeation studies, skin 
irritation studies, stability studies, in vivo antihypertensive studies, 
and other evaluation parameters. Hence, the formulation EMNP7 
was selected as the best formulation and is suitable for controlled 
release once a day formulation. Finally, it could be concluded that 
the EM loaded nanoproniosomal gel proves to be a beneficial and 
suitable alternative to the conventional dosage form for the 
treatment of hypertension. 
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